Please ensure Javascript is enabled for purposes of website accessibility

3 Speculative Biotech Stocks to Buy Now

By Keith Speights and Max Macaluso - Apr 12, 2013 at 4:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks are speculative, but the returns could be spectacular. 3 up-and-coming biotechs to look at buying now.

Health care analyst Max Macaluso recently sat down with Fool contributor Keith Speights to talk about some of the best speculative biotech plays on the market. Max and Keith discussed three companies that investors should consider: Keryx Pharmaceuticals (KERX), Sarepta Therapeutics (SRPT -0.51%), and MannKind (MNKD 5.00%).

Both Keryx and Sarepta have soared over the last year. Keryx is up a whopping 190% so far in 2013. Meanwhile, Sarepta's shares jumped nearly 50% year-to-date after an amazing run last year.

The nice run by Keryx was powered by high expectations for its kidney disease drug Zerenex. Sarepta's success has stemmed from excitement over its Duchenne muscular dystrophy drug eteplirsen.

MannKind also has enjoyed a great year so far. Shares are up nearly 80% in the first three and a half months of 2013. Investors are eagerly awaiting results from what they hope to be the final study for inhalable insulin product Afrezza.

In this video, Max and Keith talk about the prospects for each of these three speculative biotech stocks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
SRPT
$68.49 (-0.51%) $0.35
MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$4.20 (5.00%) $0.20
Keryx Biopharmaceuticals, Inc. Stock Quote
Keryx Biopharmaceuticals, Inc.
KERX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.